A novel peroxisome proliferator-activated receptor γ ligand, MCC-555, induces apoptosis via post-transcriptional regulation of NAG-1 in colorectal cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1352-1361

  Yamaguchi, Kiyoshi ^a   Lee, Seong Ho ^a   Eling, Thomas E ^b   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NETOGLITAZONE; PROTEIN NAG 1; ROSIGLITAZONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; COLORECTAL CANCER; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; REPORTER GENE; RNA DEGRADATION; RNA STABILITY; TRANSCRIPTION REGULATION;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; COLORECTAL NEOPLASMS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; PPAR GAMMA; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33745061909     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0528     Document Type: Article

References (53)

1. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.
2. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Aced Sci U S A 1998;95:8806-11.
3. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-5.
4. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Aced Sci U S A 2000;97:10990-5.
5. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
6. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002;1:357-63.
7. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR-γ. Nat Mad 1998;4: 1046-52.
8. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115:1049-55.
9. Nikitakis NG, Siavash H, Hebert C, Reynolds MA, Hamburger AW, Sauk JJ. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes down-regulation of Stat3 in human oral SCCa cells. Br J Cancer 2002;87:1396-403.
10. Rumi MA, Ishihara S, Kadowaki Y, et al. Peroxisome proliferator-activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 2004;9:1113-23.
11. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor γ-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004;10:7022-30.
12. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-53.
13. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279:6883-92.
14. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-9.
15. Reginato MJ, Bailey ST, Krakow SL, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 1998;273:32679-84.
16. Ishii S, Wasaki M, Ohe T, Ueno H, Tanaka H. MCC-555: a highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes 1996;45:141A.
17. Kumagai T, Ikezoe T, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antivity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004;10:1508-20.
18. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Aced Sci U S A 1997;94:11514-9.
19. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000; 275:20127-35.
20. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem 1998;273:13760-7.
21. Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter-Crazzolara C. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 1999;237:105-11.
22. Tan M, Wang Y, Guan K, Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci U S A 2000;97:109-14.
23. Bask SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-8.
24. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-34.
25. Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 2004;25:2425-32.
26. Lee SH, Kim JS, Yamaguchi K, Eling TE, Bask SJ. Indole-3-carbinol and 3, 3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005;328:63-9.
27. Lee SH, Yamaguchi K, Kim JS, et al. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 2006;27:972-81.
28. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1, 1-Bis(3′-indolyi)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor γ agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005;68:1782-92.
29. Yamaguchi K, Liggett JL, Kim NC, Baek SJ. Anti-proliferative effect of horehound leaf and wild cherry bark extracts on human colorectal cancer cells. Oncol Rep 2006; 15:275-81.
30. Monks A, Harris E, Hose C, Connelly J, Sausville EA. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 2003;63:766-72.
31. Yamaguchi K, Lee SH, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3β pathway. J Biol Chem 2004;279:49617-23.
32. Baek SJ, Horowitz JM, Eling TE. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 2001; 276:33384-92.
33. Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/ placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005; 280:18636-42.
34. Dixon DA. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 2004;10:635-46.
35. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003;195:356-72.
36. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
37. Pfeifer GP, Denissenko MF. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations? Environ Mol Mutagen 1998;31: 197-205.
38. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000;58:52-9.
39. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004;130:73-9.
40. Yamaguchi K, Lee SH, Kim JS, Wimalasena J, Kitajima S, Beek SJ. Activating transcription factor 3 and early growth response-1 are the novel targets of LY294002 in a PI3K independent pathway. Cancer Res 2006; 66:2376-84.
41. Sachs AB. Messenger RNA degradation in eukaryotes. Cell 1993;74: 413-21.
42. Liu J, Shen X, Nguyen VA, Kunos G, Gao B. α(l) adrenergic agonist induction of p2l(wafl/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor. J Biol Chem 2000;275:11846-51.
43. Winzen R, Gowrishankar G, Bollig F, Redich N, Resch K, Holtmann H. Distinct domains of AU-rich elements exert different functions in mRNA destabilization and stabilization by p38 mitogen-activated protein kinase or HuR. Mol Cell Biol 2004;24:4835-47.
44. Dean JL, Sully G, Clark AR, Saklatvala J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004;16:1113-21.
45. Andoh A, Shimada M, Bamba S, et al. Extracellular signal-regulated kinases 1 and 2 participate in interleukin-17 plus tumor necrosis factor-α-induced stabilization of interleukin-6 mRNA in human pancreatic myofibroblasts. Biochim Biophys Acta 2002;1591:69-74.
46. Headley VV, Tanveer R, Greene SM, Zweifach A, Port JD. Reciprocal regulation of β-adrenergic receptor mRNA stability by mitogen activated protein kinase activation and inhibition. Mol Cell Biochem 2004;258: 109-19.
47. Jijon HB, Panenka WJ, Madsen KL, Parsons HG. MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Am J Physiol Cell Physiol 2002;283:C31-41.
48. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-α (TNF-α) mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J Biol Chem 2001;276:6666-74.
49. Goillot E, Raingeaud J, Ranger A, et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Aced Sci U S A 1997;94:3302-7.
50. Ko JC, Wang YT, Yang JL. Dual and opposing roles of ERK in regulating G(1) and S-G(2)/M delays in A549 cells caused by hyperoxia. Exp Cell Res 2004;297:472-83.
51. Hsu YL, Kuo PL, Lin LT, Lin CC. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J Pharmacol Exp Ther 2005;313: 333-44.
52. Park S, Park CH, Hahm ER, et al. Activation of Raf1 and the ERK pathway in response to I-ascorbic acid in acute myeloid leukemia cells. Cell Signal 2005;17:111-9.
53. Xiao D, Choi S, Johnson DE, et al. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004;23:5594-606.